Pacific Biosciences Announces New Chief Executive Officer
07 August 2020 - 10:30PM
Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading
provider of high-quality sequencing of genomes, transcriptomes, and
epigenomes, today announced the appointment of Christian O. Henry
as President and Chief Executive Officer, effective as of September
14, 2020. Mr. Henry has served on our Board of Directors
since 2018, including as Chairman of the Board since March 2020.
Dr. John F. Milligan, a Board member since 2013, has been appointed
to succeed Mr. Henry as Chairman of the Board, also effective
September 14, 2020.
As earlier announced, Dr. Michael Hunkapiller
will retire from an active operating role at the end of the year.
As of September 14, 2020, Dr. Hunkapiller will assume the position
of Senior Fellow focused on technology development until his
retirement. Dr. Hunkapiller will also continue to serve on the
Board of Directors. Also, as earlier announced, Susan K. Barnes
retired as Chief Financial Officer today. The Board of Directors
has appointed Ben Gong to serve as interim Chief Financial Officer
until the company completes its active search for a new Chief
Financial Officer.
“We are fortunate to have someone of Christian’s caliber and
experience in the life sciences industry as the next CEO of PacBio.
We are thrilled to have him lead PacBio into our next phase of
growth,” said Dr. Milligan, newly appointed Chairman of the Board.
“Christian brings strategic, operational, and public company
experience to PacBio, with a proven track record of driving
commercial growth, all qualities that were critical in our search
for a CEO. The Board is confident that Christian will build
on Mike’s success in making PacBio a leader in genetic sequencing.
Furthermore, as a member of PacBio’s board of directors for the
past two years, Christian has a solid understanding of our products
and markets and can balance our commitment to scientific and
engineering innovation with our increasing commercial opportunity.
PacBio has ample opportunities to grow and innovate, and we believe
Christian is an ideal fit to accelerate this work. We are excited
about what the future holds under Christian’s leadership.”
“I know that I speak for everyone at PacBio in thanking Dr.
Hunkapiller for his exceptional contributions and dedication to the
company. Under his leadership, the company has developed remarkable
products and technology which have contributed to significant
advances in science and sequencing. I am pleased that he will
remain involved with PacBio and will be focused on product and
technology development and contributing as a board member,” said
Christian Henry. “I am excited to join such a highly talented and
innovative team at PacBio. I believe our current and future
products will play a significant role in accelerating the use of
sequencing technologies in both the research and clinical markets
and I look forward to working with our team to expand our presence
in these markets.”
About Pacific Biosciences Pacific Biosciences
of California, Inc. (NASDAQ: PACB) is empowering life
scientists with highly accurate long-read sequencing. The company’s
innovative instruments are based on Single Molecule,
Real-Time (SMRT®) Sequencing technology,
which delivers a comprehensive view of genomes,
transcriptomes, and epigenomes, enabling access to the
full spectrum of genetic variation in any organism. Cited in
thousands of peer-reviewed publications,
PacBio® sequencing systems are in use by scientists
around the world to drive discovery in human biomedical
research, plant and animal sciences, and microbiology.
Forward-Looking Statements
All statements in this press release that are
not historical are forward-looking statements, including, among
other things, statements relating to market leadership, potential
development and commercialization of products, future uses, quality
or performance of, or benefits of using, products or technologies,
plans for growth and success, the search for a new Chief
Financial Officer, and other future events. You should not place
undue reliance on forward-looking statements because they involve
known and unknown risks, uncertainties, changes in circumstances
and other factors that are, in some cases, beyond Pacific
Biosciences’ control and could cause actual results to differ
materially from the information expressed or implied by
forward-looking statements made in this press release. Factors that
could materially affect actual results can be found in Pacific
Biosciences’ most recent filings with the Securities and
Exchange Commission, including Pacific Biosciences’ most recent
reports on Forms 8-K, 10-K and 10-Q, and include those listed under
the caption “Risk Factors.” Pacific Biosciences undertakes no
obligation to revise or update information in this press release to
reflect events or circumstances in the future, even if new
information becomes available.
ContactsInvestors: Trevin Rard
650.521.8450 ir@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Apr 2024 to May 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From May 2023 to May 2024